Related Experiment Videos
[Clinical studies with salazopyrine--consequences and perspectives]
Zeitschrift Fur Rheumatologie
|March 1, 1987
Summary
Sulphasalazine (SASP) is an effective long-acting antirheumatic drug for rheumatoid arthritis and ankylosing spondylitis. Early treatment with SASP shows better tolerance and efficacy, with ongoing research into its effects on radiological progression and other rheumatic conditions.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Medicine
Background:
- Sulphasalazine (SASP) is a well-established long-acting antirheumatic drug.
- Its efficacy has been demonstrated in placebo-controlled and comparative trials for rheumatoid arthritis.
Purpose of the Study:
- To review the established efficacy and tolerance of SASP in rheumatoid arthritis.
- To explore the potential of SASP in other rheumatic conditions like ankylosing spondylitis, reactive arthritis, and juvenile rheumatoid arthritis.
- To identify open questions regarding SASP's effect on radiological progression and its differential indications.
Main Methods:
- Review of placebo-controlled studies and comparative trials.
- Analysis of open trials in various rheumatic disorders.
Main Results:
- SASP demonstrates early treatment effects and better tolerance in rheumatoid arthritis, suitable for early and advanced disease stages.
- Positive results in placebo-controlled studies for ankylosing spondylitis suggest potential for long-acting antiphlogistic therapy.
- Promising treatment effects observed in open trials for reactive and juvenile rheumatoid arthritis.
Conclusions:
- SASP is a valuable therapeutic option for rheumatoid arthritis, particularly in early treatment and for patients intolerant to other therapies.
- Emerging evidence supports the investigation of SASP for ankylosing spondylitis, reactive arthritis, and juvenile rheumatoid arthritis.
- Further clinical studies are required to establish precise indications, benefit-risk profiles, and optimal treatment modalities for SASP in these conditions.